title: Persistence of cholinesterase inhibitor treatment in dementia: insights from a naturalistic study.
abstract: BACKGROUND
  Cholinesterase inhibitors (ChEI) are widely used in dementia, but there is a lack of practice guidelines in case of intolerance or absence of perceived effect.
  
  
  METHODS
  Two hundred and forty patients (mean age 77 years, SD 6.3, 66% female) with Alzheimer's disease or Lewy body dementia were prescribed a ChEI and evaluated annually under conditions of standard practice. Of these, 152 patients maintained, 36 switched, and 52 abandoned ChEI treatment.
  
  
  RESULTS
  Less behavioural disturbance and less cognitive deterioration were observed, respectively, at the 3- and 4-year follow-up assessments in the patients who maintained the first prescribed ChEI (p < 0.05). Cognitive benefits were reinforced in the patients who experienced some adverse event, but no benefits were observed when the patient or caregiver did not perceive an effect.
  
  
  CONCLUSIONS
  Maintenance of the first prescribed ChEI was supported when some benefit was perceived by the patient or caregiver, even in cases of nonserious adverse events.
authors: Hermanos Sangro Specialties Clinic, Service of Neurology, Gregorio Marañón University Hospital, Madrid, Spain ; Alzheimer Disease Research Unit, Alzheimer Center Reina Sofía Foundation, CIEN Foundation, Carlos III Institute of Health, Madrid, Spain.
authors: Javier
authors: J
authors: Olazarán
authors: Eloísa
authors: E
authors: Navarro
authors: José Manuel
authors: JM
authors: Rojo
keywords: Alzheimer's disease; Cholinesterase inhibitors; Lewy body dementia; Treatment persistence
references: J Psychiatr Res. 1975 Nov;12(3):189-98
references: 1202204
references: N Engl J Med. 2003 Apr 3;348(14):1333-41
references: 12672860
references: Clin Drug Investig. 2008;28(7):429-37
references: 18544003
references: Stroke. 2001 Jun;32(6):1318-22
references: 11387493
references: CMAJ. 2008 Mar 25;178(7):825-36
references: 18362376
references: Neurology. 1984 Jul;34(7):939-44
references: 6610841
references: Ann Intern Med. 2008 Mar 4;148(5):379-97
references: 18316756
references: Epidemiology. 1990 Jan;1(1):43-6
references: 2081237
references: Br J Psychiatry. 1982 Jun;140:566-72
references: 7104545
references: Int Psychogeriatr. 2011 Apr;23(3):372-8
references: 21044399
references: Drugs Aging. 2005;22(8):695-707
references: 16060719
references: Psychopharmacol Bull. 1988;24(4):653-9
references: 3249767
references: Alzheimers Res Ther. 2011 Oct 17;3(5):30
references: 21999183
references: Neurology. 1994 Dec;44(12):2308-14
references: 7991117
references: Curr Med Res Opin. 2003;19(8):707-14
references: 14687441
references: Neurology. 2005 Dec 27;65(12):1863-72
references: 16237129
references: Int J Geriatr Psychiatry. 2009 Jun;24(6):638-47
references: 19123199
references: N Engl J Med. 2012 Mar 8;366(10):893-903
references: 22397651